Women, power, and cancer: a Lancet Commission
- PMID: 37774725
- DOI: 10.1016/S0140-6736(23)01701-4
Women, power, and cancer: a Lancet Commission
Conflict of interest statement
Declaration of interests VV reports leadership or fiduciary roles in other board, society, committee or advocacy groups, paid or unpaid from the American Society of Clinical Oncology, European Society of Medical Oncology, African Organization for Research and Training in Cancer, The Lancet, eCancer, and JCO Global Oncology, and is co-editor of the Translational Oncology journal outside of the submitted work. NB-P reports receiving grants or contracts from Zuellig Pharma, Novartis, Pfizer Malaysia, AIA Sdn Bhd insurance company, and Pharmaceutical Association of Malaysia, outside of the submitted work. NB-P also reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis, Pfizer, and Roche; receives support for attending meetings or travel from Roche and the Pharmaceutical Association of Malaysia; reports participating on a Data Safety Monitoring Board or Advisory Board with Pfizer Asia Pacific, Malaysia; reports leadership or a fiduciary role in other board, society, committee, or advocacy groups, paid or unpaid with Together Against Cancer; and reports receipt of equipment, materials, drugs, medical writing, gifts, or other services from Roche Diagnostics, all outside of the submitted work. NF reports receiving consulting fees from Bristol Myers Squibb, Merck, Daiichi Sankyo, Neogenomics, Mirati, and Regeneron; and reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Janssen, and Novartis outside of the submitted work. SH reports leadership or a fiduciary role in other board, society, committee, or advocacy groups, paid or unpaid as President of GENDRO, a non-for-profit association that promotes the mainstreaming of gender in academic research and reporting practices. DM reports receiving grants or contracts from Astellas and Pfizer and reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Astellas, Janssen, Astra Zeneca, Bayer, Pfizer, Amgen, and Merck Sharp & Dohme outside of the submitted work. DM also reports support for attending meetings or travel from Ipsen, and reports participating on a Data Safety Monitoring Board or Advisory Board with Bayer, Janssen, and Ipsen, all outside of the submitted work. JB reports other financial or non-financial interests with Memorial Sloan Kettering Cancer Center (salaried as full-time postdoctoral research associate, supported internally by the Geoffrey Beene Foundation) outside of the submitted work. PSH reports other financial or non-financial interests with the National Institutes of Health, Center for Global Health (partial salary support through an Intergovernmental Personnel Act Mobility Program) outside of the submitted work. SM reports consulting fees for P-95 (based in Leuven, Belgium) outside of the submitted work. All other authors declare no competing interests.
Comment in
-
Reforms Urged to Bridge Gender Gaps in Cancer Care.Cancer Discov. 2023 Dec 12;13(12):OF1. doi: 10.1158/2159-8290.CD-NB2023-0072. Cancer Discov. 2023. PMID: 37772789
-
Women, power, and cancer: a need for change and a force for progress.Lancet. 2023 Dec 2;402(10417):2053-2055. doi: 10.1016/S0140-6736(23)01847-0. Epub 2023 Sep 26. Lancet. 2023. PMID: 37774724 No abstract available.
-
The transformative potential of law for gender and cancer.Lancet. 2023 Dec 2;402(10417):2051-2053. doi: 10.1016/S0140-6736(23)01737-3. Epub 2023 Sep 26. Lancet. 2023. PMID: 37774728 No abstract available.
-
Integrating gender into cancer research.Lancet. 2024 Apr 27;403(10437):1631. doi: 10.1016/S0140-6736(24)00593-2. Lancet. 2024. PMID: 38677852 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
